We are hosting two #pathology#openhouse events for #PathMatch22
Learn more about our work family, the cases, the culture, and *new* labs - get the scoop on it all!
#1 Sep 10, 2021 at 6 PM CT
#2 Oct 15, 2021 at 6 PM CT
Register via links in tweets below 👇🏾
Answer: Gastrointestinal Stromal Tumor (GIST). KIT (or PDGFRA) mutations are most likely to be found. Excellent work! Take a look at this thorough review on the molecular underpinnings of GIST by Blay et al: https://t.co/0n2bqbjBNd
64 yo female w/ a well-circumscribed subepithelial gastric mass. FNA performed. Diff-Quik, Pap, and cell block shown. What are your top four DDx? Immunostains and polls next! Case &📷credit: @IUraizee3MD#FNAFriday#loyolapath#loyolacyto#cytopath#GIpath (1/4)
Answer: False. FUS fusion rearrangements characterize low-grade fibromyxoid sarcoma and recurrent EWSR rearrangements are more characteristic of sclerosing epithelioid fibrosarcoma.
2. True or False: According to the WHO, identification of EWSR rearrangements are desirable for the diagnosis of low-grade fibromyxoid sarcoma and FUS rearrangements for sclerosing epithelioid fibrosarcoma. #HallwayPathQuiz#BSTpath@BrandonZelmanDO
Individuals lacking the Duffy antigen on the surfaces of red blood 🩸 cells are resistant to infections by which species of Plasmodium? Question from @MrMork87 #HallwayPathQuiz@loyolapathology#loyolapath
Answer: Denosumab. This is a giant cell tumor of bone, and denosumab inhibits the maturation of osteoclasts by binding to and inhibiting RANKL. @HallwayPathQuiz#HallwayPathQuiz